World Cancer Day 2026: BBMRI.at partners support cancer research through biobanking

World Cancer Day 2026: “United by Unique”

Observed annually on 4 February, the World Cancer Day  led by the Union for International Cancer Control (UICC), raises awareness, promotes prevention and inspires action to reduce the global cancer burden. Cancer remains the second‑leading cause of death worldwide. Yet millions of lives could be saved through effective prevention, early detection and timely treatment. More than one‑third of cancer cases can be prevented, and another third can be cured if detected early and treated properly.

The World Cancer Day campaign theme for 2025-2027 theme for 2025–2027 , “United by the Unique,” emphasises that every cancer experience is different —and that progress requires collective action that recognises each patient as individual, not just a diagnosis.

A BBMRI-ERIC story highlights examples of how the European Biobanking research infrastructure with its nodes such as BBMRI.at, contribute to the fight against cancer by supporting research.

BBMRI.at: Biobanking to support cancer research

As Austria’s national biobanking research infrastructure, BBMRI.at links academic and clinical biobanks, harmonises quality standards and streamlines responsible access to samples and data for cancer research. Through its network of biobanks and research partners, BBMRI.at ensures that patient-donated biological materials are collected ethically, processed to high standards and made available for innovative research that benefits patients today and in the future.

A key contribution of BBMRI.at lies in supporting biobanking approaches that preserve the biological uniqueness of each donor while enabling harmonised, collaborative research across institutions.

Cell bank ‘YouCell’: Patient-specific tumour models at Med Uni Graz

One example of this impact is YouCell, the cell bank at the Diagnostic and Research Institute of Pathology, Medical University of Graz (coordinator of BBMRI.at and host of Biobank Graz).

With informed consent from patients undergoing surgery for therapeutic purposes, native tumour tissues are used to establish cell cultures and cell‑based tumour models. These patient‑derived cells are cultivated and studied in the laboratory, making the powerful tools for translational cancer research.

YouCell focuses on developing standardised processes for the extraction, characterisation and long-term storage of patient-specific cell materials. Its collection includes:

• Cells from various tumour entities (such as melanoma, carcinoma and sarcomas),
• Cells from the tumour microenvironment,
• Patient-matched healthy cells from the same individual.

Why patient‑matched cells matter 

“Patient‑matched healthy cells are rarely available from commercial banks, which typically provide only isolated tumour cell lines. In contrast, the YouCell approach enables researchers to study tumour cells alongside corresponding non-malignant components, such as stromal cells or cancer-associated fibroblasts from the same patient.” emphasizes Dr Beate Rinner. She is Head of the Research Unit Translational Tissue Engineering at the Medical University of Graz.

Without matched cellular components from the same individual, in vitro systems have limited translational relevance. Preserving each donor’s unique biological profile—while supporting standardised, collaborative research—ensures studies better reflect real‑world patient needs.

Biobanking for better health

On World Cancer Day 2026, BBMRI.at underscores how biobanking unites unique patient contributions with collaborative research for better health. Initiatives like YouCell demonstrate how ethically collected, well-characterised biospecimens can accelerate cancer research and help translate scientific insights into better diagnostics and therapies— with the individual patient at the centre.